Antitumor activity was also seen in immune–deficient mice implanted with TRAIL sensitive NSCLC cells in which intratumoral injection of autologous activated CTLs resulted in TRAIL-R2-dependent tumor cell death (35). This evidence concerns the gene TNFRSF10B and non-small cell lung carcinoma.